Headlands Technologies LLC trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 60.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,084 shares of the company's stock after selling 25,987 shares during the period. Headlands Technologies LLC's holdings in Johnson & Johnson were worth $2,471,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in JNJ. Invenio Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 3.7% during the 4th quarter. Invenio Wealth Partners LLC now owns 3,404 shares of the company's stock valued at $492,000 after acquiring an additional 120 shares during the last quarter. Lokken Investment Group LLC lifted its position in Johnson & Johnson by 1.7% during the fourth quarter. Lokken Investment Group LLC now owns 15,199 shares of the company's stock valued at $2,198,000 after purchasing an additional 247 shares during the last quarter. Geode Capital Management LLC grew its stake in Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after buying an additional 1,561,036 shares in the last quarter. Nemes Rush Group LLC increased its holdings in shares of Johnson & Johnson by 14.6% in the 4th quarter. Nemes Rush Group LLC now owns 55,954 shares of the company's stock worth $8,092,000 after buying an additional 7,114 shares during the last quarter. Finally, StoneX Group Inc. raised its position in shares of Johnson & Johnson by 40.5% during the 4th quarter. StoneX Group Inc. now owns 42,849 shares of the company's stock valued at $6,197,000 after buying an additional 12,359 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 7.6 %
Shares of NYSE JNJ traded down $12.60 during trading hours on Tuesday, hitting $153.25. The company's stock had a trading volume of 23,293,291 shares, compared to its average volume of 7,720,065. The business has a 50-day simple moving average of $159.16 and a 200-day simple moving average of $155.99. The stock has a market cap of $369.30 billion, a price-to-earnings ratio of 23.04, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. The business's revenue was up 5.3% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. Johnson & Johnson's dividend payout ratio is 74.59%.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. Barclays upped their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Tuesday, January 28th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. Finally, Bank of America lifted their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research note on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $171.33.
Read Our Latest Analysis on JNJ
Insider Activity at Johnson & Johnson
In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
